iShares Biotechnology ETF
826 hedge funds and large institutions have $4.56B invested in iShares Biotechnology ETF in 2022 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 228 increasing their positions, 302 reducing their positions, and 73 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less funds holding in top 10
Funds holding in top 10: →
23% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 73
25% less repeat investments, than reductions
Existing positions increased: 228 | Existing positions reduced: 302
64% less call options, than puts
Call options by funds: $257M | Put options by funds: $721M
Holders
826
Holding in Top 10
14
Calls
$257M
Puts
$721M
Top Buyers
| 1 | +$76.3M | |
| 2 | +$34M | |
| 3 | +$32.7M | |
| 4 |
IUHSA
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
|
+$26.4M |
| 5 |
CB
Commerce Bank
Kansas City,
Missouri
|
+$23.6M |
Top Sellers
| 1 | -$130M | |
| 2 | -$61.5M | |
| 3 | -$51.8M | |
| 4 |
E
Ergoteles
New York
|
-$39M |
| 5 |
Goldman Sachs
New York
|
-$28.9M |